ArticleBiotechnology journal2026
Spatial Engineering of Yarrowia lipolytica for the Biosynthesis of Capsanthin.
Article in Biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Capsanthin is a high-value tetraterpenoid widely utilized in the food, cosmetic, and pharmaceutical industries. However, its traditional production via plant extraction and chemical synthesis faces severe sustainability and cost constraints. The oleaginous yeast Yarrowia lipolytica (Y. lipolytica) offers a superior chassis due to its robust mevalonate pathway and abundant lipid droplets for pigment sequestration. In this study, we systematically engineered Y. lipolytica for the de novo biosynthesis of capsanthin. By heterologously co-expressing of Capsicum annuum capsanthin/capsorubin synthase (CaCCS) and Arabidopsis thaliana zeaxanthin epoxidase (AtZEP), we achieved the first reported biosynthesis of capsanthin in Y. lipolytica. Combinatorial screening revealed that full-length sequences of CaCCS and AtZEP yielded optimal production of 6.92 mg/L. To further enhance the productivity of capsanthin, we evaluated spatial compartmentalization strategies. The results demonstrated that targeting the biosynthetic enzymes to the peroxisome via Ser-Lys-Leu (SKL) tags successfully increased the titer to 8.8 mg/L by leveraging its specialized lipophilic and redox microenvironment. Finally, a 5-L fed-batch fermentation was conducted, achieving a maximum capsanthin titer of 48.15 mg/L. This work provides a sustainable and scalable alternative to plant extraction and chemical synthesis for capsanthin production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.